

Prof Edward John Wild MA MB BChir PhD FRCP
e.wild@ucl.ac.uk
GMC 6039798

CURRENT POSTS

- 2020 - present **Professor of Neurology**, University College London
2015 - present **Consultant Neurologist**, National Hospital for Neurology & Neurosurgery,
Queen Square, London (UCLH NHS Trust)
2018 - present **Associate Director**, UCL Huntington's Disease Centre

PREVIOUS POSTS

- 2015 - 2019 Principal Research Fellow, UCL Institute of Neurology
2011 - 2015 NIHR Clinical Lecturer in Neurology UCL Institute of Neurology;
Honorary Specialist Registrar, National Hospital for Neurology & Neurosurgery
2008 - 2010 Specialty Registrar in Neurology, Severn Deanery
2005 - 2008 Clinical Research Fellow, UCL Institute of Neurology, London
2005 - 2005 Senior House Officer Neurology, National Hospital for Neurology & Neurosurgery

EDUCATIONAL QUALIFICATIONS

- 2018 Fellow of the Royal College of Physicians
2015 MRCP (Neurology), Royal College of Physicians
2015 Certificate of Completion of Training in Neurology, JRCPTB
2010 Specialty Certificate in Neurology, Royal College of Physicians
2009 PhD in Neuroscience, UCL (*Identification & evaluation of biomarkers for HD*)
2005 Membership of the Royal College of Physicians (UK)
2001 MB BChir, Cambridge University School of Clinical Medicine
1999 MA Medical Sciences, Christ's College, Cambridge University

SELECTED PROFESSIONAL ACTIVITIES

- 2020 - present **European academy of Neurology**: Translational Neurology Panel member
2020 - present **UCL LGBTQ+ Steering Group**: Member
2019 - present **Association of British Neurologists**: Neurogenetics Advisory Board member
2017 - present **Journal of Huntington's Disease**: Associate Editor
2017 - present **Critical Path Institute** HD Regulatory Science Consortium: Coordinating Committee member
2016 - present **HDClarity Study**: Global Chief Investigator
2013 - present **European HD Network Biomarkers Working Group**: Lead Facilitator
2011 - present **Huntington's Disease Association**: Medical Advisory Board member
2010 - 2014 **European HD Network Scientific & Bioethics Advisory Board**: elected member
2010 - present **All-Party Parliamentary Group on Huntington's Disease**: Steering Committee member
2010 - present **HDBuzz** research news platform: Founder and Editor-in-Chief

PRIZES AND HONOURS

- 2017, 2015 Huntington Study Group Insight of the Year Award
2014 Huntington's Disease Society of America Researcher of the Year Award
2012 Huntington Society of Canada Community Leadership Award
2009 Queen Square Prize in Neurology

GRANT FUNDING

- 2020 CHDI Foundation, Senior Fellowship (£826k)
2020 Hoffman La Roche, Digital Biomarker Study (£839k as PI)
2019 European Huntington's Disease Network Seed Fund (£33k as PI)
2019 HD Society of America postdoctoral fellowship for L Byrne (£165k as supervisor)
2019 Hereditary Disease Foundation fellowship for L Byrne (£96k as supervisor)
2015 CHDI Foundation, HDClarity (£1.8m as global CI)
2015 Wellcome Trust Multiuser Equipment Grant (£101k as co-PI)
2014 - 2019 MRC Clinician Scientist Fellowship (£1.2m)

SELECTED PUBLICATIONS

Publications 86 | **Book chapters** 6 | **Citations** 11,627 | **H-index** 46 | **i10 index** 78

Selected papers 2015-present

1. Byrne ... & Wild 2022. *Neurofilament Light Protein as a Potential Blood Biomarker for Huntington's Disease in Children*. **Movement Disorders**. doi:10.1002/mds.29027
2. Rodrigues ... & Wild 2021. *Kynurenine pathway metabolites in cerebrospinal fluid and blood as potential biomarkers in Huntington's disease*. **J Neurochem** 158.
3. Rodrigues/Byrne ... & Wild 2020. *Mutant huntingtin and neurofilament light have distinct longitudinal dynamics in Huntington's disease*. **Science Translational Medicine**.
4. Tabrizi, Flower & Wild 2020. *Huntington disease: new insights into molecular pathogenesis and therapeutic opportunities*. **Nature Reviews Neurology**. doi:10.1038/s41582-020-0389-4.
5. Lowe ... & Wild 2020. *Cerebrospinal fluid endo-lysosomal proteins as potential biomarkers for Huntington's disease*. **PLoS One**. 15(8):e0233820-e0233820.
6. Scahill, ... Wild, Rees, Robbins, Sahakian, Langbehn & Tabrizi. *Biological and clinical characteristics of gene carriers far from predicted onset in the Huntington's disease Young Adult Study (HD-YAS): a cross-sectional analysis*. **Lancet Neurology** 19(6):502-512.
7. Tabrizi, Leavitt, Landwehrmeyer, Wild et al 2019. *Targeting Huntingtin Expression in Patients with Huntington's Disease*. **New England Journal of Medicine**.
8. Byrne/Rodrigues ... & Wild 2018. *Evaluation of mutant huntingtin and neurofilament proteins as potential markers in Huntington's disease*. **Science Translational Medicine**. 12:458.
9. Byrne ... & Wild 2018. *Cerebrospinal fluid neurogranin and TREM2 in Huntington's disease*. **Scientific Reports** 9:4260.
10. Johnson ... & Wild 2018. *Neurofilament light protein in blood predicts regional atrophy in Huntington Disease*. **Neurology** 90:e717-e323.
11. Wild & Tabrizi 2017. *Therapies targeting DNA & RNA in Huntington's disease*. **Lancet Neurology** 16:837.
12. Byrne ... & Wild 2017. *Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis*. **Lancet Neurology** 16:601.
13. Rodrigues ... & Wild 2016. *Cerebrospinal Fluid Inflammatory Biomarkers Reflect Clinical Severity in Huntington's Disease*. **PLoS One** 11:e0163479.
14. Rodrigues ... & Wild 2016. *Cerebrospinal fluid total tau concentration predicts clinical phenotype in Huntington's disease*. **J Neurochem** 139:22.
15. Wild et al 2015. *Quantification of mutant huntingtin protein in cerebrospinal fluid from Huntington's disease patients*. **Journal of Clinical Investigation** 125:1979.

Selected papers pre-2015

1. Bates ... Wild & Tabrizi. *Huntington Disease*. **Nature Reviews Disease Primers** 1:15005.
2. Wild & Tabrizi 2012. *Premanifest & Early Huntington's Disease*. In **Huntington's Disease**, 3rd ed. Ed G Bates, L Jones & S Tabrizi. Oxford University Press.
3. Weiss, Traeger, Wild et al 2012. *Mutant huntingtin fragmentation in immune cells tracks Huntington's disease progression*. **Journal of Clinical Investigation** 10:3731-6.
4. Wild et al 2010. *Rate and acceleration of whole-brain atrophy in premanifest and early Huntington's disease*. **Mov Disord** 25:888-95.
5. Wild/Henley et al 2009. *Whole-brain atrophy as a measure of progression in premanifest and early Huntington's disease*. **Mov Disord** 24:932-6.
6. Wild / Björkqvist et al 2008. *A novel pathogenic pathway of immune activation detectable before clinical onset in Huntington's disease*. **Journal of Experimental Medicine**. 205: 1869-77.
7. Runne, Kuhn, Wild et al 2007. *Analysis of potential transcriptomic biomarkers for Huntington's disease in peripheral blood*. **PNAS** 104:14424-9